Abstract
The increase in the therapeutic arsenal in the last 20 years, has given rise to changes in treating colorectal cancer (CRC) with only pyrimidines to combine several cytotoxic drugs. However, the present question is to determine the optimal sequence of this combination. This review presents an update of data on chemical and clinical features of chemotherapy used for colorectal cancer and the mechanisms of cellular resistance and potential predictive and prognostic biomarkers, which may contribute to a better selection of a therapeutic strategy.
Keywords: Bioanalytical methods, biomarkers, chemotherapy, chemoresistance, colorectal cancer, drug combination, fluoropyrimidines, future trends, irinotecan, oxaliplatin, raltitrexed.
Current Medicinal Chemistry
Title:Current Trends in the Chemotherapy of Colorectal Cancer
Volume: 19 Issue: 26
Author(s): M. A. Berciano-Guerrero, J. C. Villa-Guzman, R. Acosta-Guerrero, G. Castaneda-Penalvo and J. Rodriguez-Flores
Affiliation:
Keywords: Bioanalytical methods, biomarkers, chemotherapy, chemoresistance, colorectal cancer, drug combination, fluoropyrimidines, future trends, irinotecan, oxaliplatin, raltitrexed.
Abstract: The increase in the therapeutic arsenal in the last 20 years, has given rise to changes in treating colorectal cancer (CRC) with only pyrimidines to combine several cytotoxic drugs. However, the present question is to determine the optimal sequence of this combination. This review presents an update of data on chemical and clinical features of chemotherapy used for colorectal cancer and the mechanisms of cellular resistance and potential predictive and prognostic biomarkers, which may contribute to a better selection of a therapeutic strategy.
Export Options
About this article
Cite this article as:
A. Berciano-Guerrero M., C. Villa-Guzman J., Acosta-Guerrero R., Castaneda-Penalvo G. and Rodriguez-Flores J., Current Trends in the Chemotherapy of Colorectal Cancer, Current Medicinal Chemistry 2012; 19(26) . https://dx.doi.org/10.2174/092986712803251494
DOI https://dx.doi.org/10.2174/092986712803251494 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Structural Findings and Molecular Modeling Approach of a TFPI-Like Inhibitor
Protein & Peptide Letters The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Chemical Biology Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer
Current Drug Targets A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine